We recently adapted the 18-gene MEK activation signature from use in fresh frozen CRC samples to more clinically available, archived formalin-fixed, paraffin-embedded (FFPE) tissues [33], as a means to predict RAS/MEK pathway dependence regardless of RAS/RAF mutation status. This evidence concerns the gene MAP2K7 and colorectal carcinoma.